ICU Medical (NASDAQ:ICUI) Given New $209.00 Price Target at KeyCorp

ICU Medical (NASDAQ:ICUI) had its price objective lifted by KeyCorp from $198.00 to $209.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical instruments supplier’s stock. KeyCorp’s target price would indicate a potential upside of 14.62% from the stock’s previous close.

ICUI has been the subject of several other reports. Jefferies Financial Group initiated coverage on shares of ICU Medical in a research note on Monday, October 14th. They set a “hold” rating and a $183.00 target price for the company. StockNews.com lowered shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Tuesday. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Wednesday. Finally, Raymond James lifted their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

ICU Medical Stock Performance

ICU Medical stock traded up $4.33 during midday trading on Wednesday, hitting $182.34. The stock had a trading volume of 286,771 shares, compared to its average volume of 273,349. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76. ICU Medical has a 52-week low of $82.82 and a 52-week high of $193.30. The company has a market capitalization of $4.45 billion, a PE ratio of -61.77 and a beta of 0.66. The firm’s fifty day moving average is $175.85 and its two-hundred day moving average is $141.75.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Tuesday, November 12th. The medical instruments supplier reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.35. The business had revenue of $580.07 million for the quarter, compared to analysts’ expectations of $574.77 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. On average, research analysts forecast that ICU Medical will post 3.81 EPS for the current year.

Insider Buying and Selling

In related news, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the sale, the vice president now owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total value of $1,961,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $17,096,771.78. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the sale, the vice president now directly owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 50,502 shares of company stock valued at $8,445,976. Insiders own 6.70% of the company’s stock.

Institutional Trading of ICU Medical

Institutional investors have recently bought and sold shares of the stock. Scout Investments Inc. grew its stake in ICU Medical by 16.3% during the 1st quarter. Scout Investments Inc. now owns 51,819 shares of the medical instruments supplier’s stock valued at $5,463,000 after purchasing an additional 7,272 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of ICU Medical by 441.7% during the 2nd quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock valued at $691,000 after buying an additional 4,744 shares during the last quarter. Sei Investments Co. lifted its holdings in shares of ICU Medical by 52.1% in the 1st quarter. Sei Investments Co. now owns 28,586 shares of the medical instruments supplier’s stock valued at $3,068,000 after buying an additional 9,793 shares during the period. Silvercrest Asset Management Group LLC grew its holdings in ICU Medical by 109.4% during the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock worth $29,882,000 after acquiring an additional 145,485 shares during the period. Finally, Vanguard Group Inc. boosted its position in ICU Medical by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock worth $263,226,000 after purchasing an additional 11,991 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.